Page 21 - NON-INVASIVE TESTS FOR EVALUATION OF LIVER DISEASE SEVERITY AND PROGNOSIS
P. 21
Clinical Practice Guidelines sustained virological response in hepatitis C virus patients with cirrhosis.
Hepatology 2012;56:532–543.
Marco Arrese: [7] Gailhouste L, Le Grand Y, Odin C, Guyader D, Turlin B, Ezan F, et al. Fibrillar
– Grant and research support: Fondo Nacional de Desarrollo collagen scoring by second harmonic microscopy: a new tool in the
assessment of liver fibrosis. J Hepatol 2010;52:398–406.
Cientı´fico y Tecnolo´ gico (FONDECYT 1110455) and the [8] Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al.
Comisio´ n Nacional de Investigacio´ n Cientı´fica y Tecnolo´ gica Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:
(grant PFB 12/2007, Basal Centre for Excellence in Science 696–699.
and Technology) from the government of Chile [9] Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al.
– Advisory Boards: none Sampling error and intraobserver variation in liver biopsy in patients with
– Speaking and teaching: none chronic HCV infection. Am J Gastroenterol 2002;97:2614–2618.
[10] Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in
Nezam Afdhal: chronic hepatitis C. Hepatology 2003;38:1449–1457.
– Grant and research support: Merck, Vertex, Gilead, AbbVie, [11] Brunetti E, Silini E, Pistorio A, Cavallero A, Marangio A, Bruno R, et al. Coarse
vs. fine needle aspiration biopsy for the assessment of diffuse liver disease
BMS from hepatitis C virus-related chronic hepatitis. J Hepatol 2004;40:
– Advisory Boards: Merck, Gilead, Echosens, Glaxo Smith Kline, 501–506.
[12] Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al.
Ligand, Springbank, Kadmon, Jannsen, AbbVie, Achillion, Sources of variability in histological scoring of chronic viral hepatitis.
Sandhill Scientific Hepatology 2005;41:257–264.
– Speaking and teaching: none [13] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:
495–500.
Pierre Bedossa: [14] Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following
– Grant and research support: none percutaneous liver biopsy. A multicentre retrospective study on 68,276
– Advisory Boards: none biopsies. J Hepatol 1986;2:165–173.
– Speaking and teaching: Gilead, Genfit, Echosens, Intercep [15] Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver
histology markers. J Hepatol 2009;50:36–41.
Mireen Friedrich-Rust: [16] Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating
– Grant and research support: Echosens, Siemens Medical, the efficacy of diagnostic tests. N Engl J Med 1978;299:926–930.
[17] Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V,
Supersonic Imagine et al. Standardization of ROC curve areas for diagnostic evaluation of liver
– Advisory Boards: none fibrosis markers based on prevalences of fibrosis stages. Clin Chem
– Speaking and teaching: Echosens, Siemens Medical 2007;53:1615–1622.
[18] Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, et al. The
Kwang-Hyub Han: impact of liver disease aetiology and the stages of hepatic fibrosis on the
– Grant and research support: Medigen co., Eisai co. and KOWA performance of non-invasive fibrosis biomarkers: an international study of
2411 cases. Aliment Pharmacol Ther 2011;34:1202–1216.
co. [19] Obuchowski NA. An ROC-type measure of diagnostic accuracy when the
– Advisory Boards: Eisai co. and KOWA co. gold standard is continuous-scale. Stat Med 2006;25:481–493.
– Speaking and teaching: nothing to disclose [20] Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al.
GRADE guidelines: 14. Going from evidence to recommendations: the
Massimo Pinzani: significance and presentation of recommendations. J Clin Epidemiol
– Grant and research support: none 2013;66:719–725.
– Advisory Boards: Intercept, Abbvie, USB Cell Tech, Silence [21] Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T.
Biochemical markers of liver fibrosis in patients with hepatitis C virus
Therapeutics infection: a prospective study. Lancet 2001;357:1069–1075.
– Speaking and teaching: Gilead, BMS, Jansen, Norgine, Gore, [22] Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E,
et al. Identification of chronic hepatitis C patients without hepatic fibrosis
MSD, Echosens by a simple predictive model. Hepatology 2002;36:986–992.
[23] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram
References HS, et al. A simple noninvasive index can predict both significant fibrosis
and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:
[1] Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The 518–526.
long-term pathological evolution of chronic hepatitis C. Hepatology [24] Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation
1996;23:1334–1340. of a panel of non-invasive serum markers to differentiate mild from
moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J
[2] Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Hepatol 2004;41:935–942.
et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol [25] Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, et al.
agreement and ability to predict liver-related mortality. Hepatology Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1
2011;53:1874–1882. and TIMP-2 as serum markers of liver fibrosis in patients with chronic
hepatitis C: comparison with PIIINP and hyaluronic acid. Am J
[3] Intraobserver and interobserver variations in liver biopsy interpretation in Gastroenterol 2004;99:271–279.
patients with chronic hepatitis C. The French METAVIR Cooperative Study [26] Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved
Group. Hepatology 1994;20:15–20. prediction of fibrosis in chronic hepatitis C using measures of insulin
resistance in a probability index. Hepatology 2004;39:1239–1247.
[4] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic [27] Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore:
hepatitis C. The METAVIR cooperative study group. Hepatology 1996;24: an accurate validated predictor of liver fibrosis in chronic hepatitis C
289–293. infection. Clin Chem 2005;51:1867–1873.
[28] Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al.
[5] Tsochatzis E, Bruno S, Isgro G, Hall A, Theocharidou E, Manousou P, et al. Predicting cirrhosis in patients with hepatitis C based on standard
Collagen proportionate area is superior to other histological methods for laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:
sub-classifying cirrhosis and determining prognosis. J Hepatol 2014;60: 282–292.
948–954. [29] Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-
infected patients can be excluded using an index of standard biochemical
[6] D’Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, et al. A serum markers. Scand J Gastroenterol 2005;40:867–872.
morphometric and immunohistochemical study to assess the benefit of a
20 Journal of Hepatology 2015 vol. xxx j xxx–xxx
Please cite this article in press as: EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J
Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2015.04.006
Hepatology 2012;56:532–543.
Marco Arrese: [7] Gailhouste L, Le Grand Y, Odin C, Guyader D, Turlin B, Ezan F, et al. Fibrillar
– Grant and research support: Fondo Nacional de Desarrollo collagen scoring by second harmonic microscopy: a new tool in the
assessment of liver fibrosis. J Hepatol 2010;52:398–406.
Cientı´fico y Tecnolo´ gico (FONDECYT 1110455) and the [8] Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al.
Comisio´ n Nacional de Investigacio´ n Cientı´fica y Tecnolo´ gica Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:
(grant PFB 12/2007, Basal Centre for Excellence in Science 696–699.
and Technology) from the government of Chile [9] Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al.
– Advisory Boards: none Sampling error and intraobserver variation in liver biopsy in patients with
– Speaking and teaching: none chronic HCV infection. Am J Gastroenterol 2002;97:2614–2618.
[10] Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in
Nezam Afdhal: chronic hepatitis C. Hepatology 2003;38:1449–1457.
– Grant and research support: Merck, Vertex, Gilead, AbbVie, [11] Brunetti E, Silini E, Pistorio A, Cavallero A, Marangio A, Bruno R, et al. Coarse
vs. fine needle aspiration biopsy for the assessment of diffuse liver disease
BMS from hepatitis C virus-related chronic hepatitis. J Hepatol 2004;40:
– Advisory Boards: Merck, Gilead, Echosens, Glaxo Smith Kline, 501–506.
[12] Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al.
Ligand, Springbank, Kadmon, Jannsen, AbbVie, Achillion, Sources of variability in histological scoring of chronic viral hepatitis.
Sandhill Scientific Hepatology 2005;41:257–264.
– Speaking and teaching: none [13] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:
495–500.
Pierre Bedossa: [14] Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following
– Grant and research support: none percutaneous liver biopsy. A multicentre retrospective study on 68,276
– Advisory Boards: none biopsies. J Hepatol 1986;2:165–173.
– Speaking and teaching: Gilead, Genfit, Echosens, Intercep [15] Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver
histology markers. J Hepatol 2009;50:36–41.
Mireen Friedrich-Rust: [16] Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating
– Grant and research support: Echosens, Siemens Medical, the efficacy of diagnostic tests. N Engl J Med 1978;299:926–930.
[17] Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V,
Supersonic Imagine et al. Standardization of ROC curve areas for diagnostic evaluation of liver
– Advisory Boards: none fibrosis markers based on prevalences of fibrosis stages. Clin Chem
– Speaking and teaching: Echosens, Siemens Medical 2007;53:1615–1622.
[18] Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, et al. The
Kwang-Hyub Han: impact of liver disease aetiology and the stages of hepatic fibrosis on the
– Grant and research support: Medigen co., Eisai co. and KOWA performance of non-invasive fibrosis biomarkers: an international study of
2411 cases. Aliment Pharmacol Ther 2011;34:1202–1216.
co. [19] Obuchowski NA. An ROC-type measure of diagnostic accuracy when the
– Advisory Boards: Eisai co. and KOWA co. gold standard is continuous-scale. Stat Med 2006;25:481–493.
– Speaking and teaching: nothing to disclose [20] Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al.
GRADE guidelines: 14. Going from evidence to recommendations: the
Massimo Pinzani: significance and presentation of recommendations. J Clin Epidemiol
– Grant and research support: none 2013;66:719–725.
– Advisory Boards: Intercept, Abbvie, USB Cell Tech, Silence [21] Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T.
Biochemical markers of liver fibrosis in patients with hepatitis C virus
Therapeutics infection: a prospective study. Lancet 2001;357:1069–1075.
– Speaking and teaching: Gilead, BMS, Jansen, Norgine, Gore, [22] Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E,
et al. Identification of chronic hepatitis C patients without hepatic fibrosis
MSD, Echosens by a simple predictive model. Hepatology 2002;36:986–992.
[23] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram
References HS, et al. A simple noninvasive index can predict both significant fibrosis
and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:
[1] Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The 518–526.
long-term pathological evolution of chronic hepatitis C. Hepatology [24] Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation
1996;23:1334–1340. of a panel of non-invasive serum markers to differentiate mild from
moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J
[2] Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Hepatol 2004;41:935–942.
et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol [25] Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, et al.
agreement and ability to predict liver-related mortality. Hepatology Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1
2011;53:1874–1882. and TIMP-2 as serum markers of liver fibrosis in patients with chronic
hepatitis C: comparison with PIIINP and hyaluronic acid. Am J
[3] Intraobserver and interobserver variations in liver biopsy interpretation in Gastroenterol 2004;99:271–279.
patients with chronic hepatitis C. The French METAVIR Cooperative Study [26] Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved
Group. Hepatology 1994;20:15–20. prediction of fibrosis in chronic hepatitis C using measures of insulin
resistance in a probability index. Hepatology 2004;39:1239–1247.
[4] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic [27] Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore:
hepatitis C. The METAVIR cooperative study group. Hepatology 1996;24: an accurate validated predictor of liver fibrosis in chronic hepatitis C
289–293. infection. Clin Chem 2005;51:1867–1873.
[28] Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al.
[5] Tsochatzis E, Bruno S, Isgro G, Hall A, Theocharidou E, Manousou P, et al. Predicting cirrhosis in patients with hepatitis C based on standard
Collagen proportionate area is superior to other histological methods for laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:
sub-classifying cirrhosis and determining prognosis. J Hepatol 2014;60: 282–292.
948–954. [29] Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-
infected patients can be excluded using an index of standard biochemical
[6] D’Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, et al. A serum markers. Scand J Gastroenterol 2005;40:867–872.
morphometric and immunohistochemical study to assess the benefit of a
20 Journal of Hepatology 2015 vol. xxx j xxx–xxx
Please cite this article in press as: EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J
Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2015.04.006
